StockData

Heron Therapeutics vs UroGen Pharma

HRTX and URGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HRTX and URGN compare

UroGen Pharma is the larger company, worth 25 times as much as Heron Therapeutics ($1.4B against $54.0M).

UroGen Pharma grew revenue faster over the last twelve months (100% versus 0.99% for Heron Therapeutics).

Heron Therapeutics keeps more of each dollar of sales as profit, with a net margin of −22.5% compared with −51.7% at UroGen Pharma.

Heron Therapeutics scores higher on the StockData Score (8 against 6 for UroGen Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHRTXURGN
Size and price
Market cap$54.0M$1.4B
Share price$0.284$28.10
Change, 1 year−74.4%17.5%
Change, 5 years−97.0%131%
Beta (5Y)2.942.83
Employees128291
StockData Score
Total score8 (better)6
Valuation score00
Growth score13 (better)
Performance score22
Health score5 (better)1
Dividend score00
Valuation
P/S0.4× (better)7.3×
P/B7.8×–
FCF yield−22.5%−11.6% (better)
Growth
Revenue growth (TTM)0.99%100% (better)
Revenue growth, 5Y average11.8%56.2% (better)
Profitability
Gross margin70.1%90.8% (better)
Operating margin−7.2% (better)−35.3%
Net margin−22.5% (better)−51.7%
FCF margin−8.0% (better)−84.3%
Financial health
Debt / equity0.00–
Current ratio2.493.80 (better)
Altman Z-score−9.60−2.69 (better)
Piotroski F-score4 (better)0
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions70.4%86.8%
Held by insiders21.6%5.6%
Insider net buying, 12 months–−$4.5M
Short interest, % of float22.8%11.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.